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Objective: Sentinel node biopsy (SNB) has become standard of care in early stage vulvar
cancer. As the correlation of isotope count with the presence of metastases remains unclear,
often several active nodes are excised per groin. This can result in increased morbidity in
node-negative disease despite of SNB. In the current analysis, we assess whether resection of
the hottest node could be sufficient to detect sentinel lymph node (SLN) metastasis.
Methods: Patients with primary vulvar cancer receiving an SNB with radioactive tracer at
the UniversityMedical Center Hamburg-Eppendorf between 2008 and 2015 were evaluated.
Results: A total of 145 patients with SNB were analyzed; thereof, 144 underwent bilateral
SNB, resulting in 289 analyzed groins. A median of 2 SLNs (range, 1Y7) per groin were
removed. From 94 (32.5%) of 289 groins, more than 2 SLNs were excised. Median overall
SLN isotope count was 1400 cps. In 50 groins, a positive SLN was detected (unilateral in 38
patients, bilateral in 6). The median number of positive SLN per groin was 1 (range, 1Y4).
The SLN with the highest isotope count carried metastases in 36 (78.3%) of 46 groins (in 4
cases, the highest count was unknown). In 10 (21.7%) of 46 positive groins, the SLN with
the highest count was not the metastatic SLN (9/10 second highest count). Median count of
these 10 SLN was 60% of the highest count with a range from 11.0% to 74.0%.
Conclusions: The highest isotope count does not reliably detect the positive SLN in vulvar
cancer. To prevent mostly fatal groin recurrences, surgeons should continue to remove all
SLN accumulating relevant radioactive tracer over background activity.
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S ince publicationof the results of theGroningen InternationalStudy on Sentinel Nodes in Vulvar Cancer (GROINSS-V1)
in 2008 and the Gynecological Oncology Group 173 trial in
2012, sentinel node biopsy (SNB) is a widely accepted and
reliable surgical staging method for clinically node-negative
early stage vulvar cancer.1,2 In general, the sentinel lymph
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node (SLN) is defined as the first node draining lymphatic fluid
from the tumor site. Consequently, if nodal metastases occur,
the tumor cells travel to the SLN and can ideally be diagnosed
via biopsy of this previously marked node.3 Sentinel lymph
node identification in patients with vulvar cancer has been first
described by Levenback et al.4,5 In the early 1990s, they
demonstrated the feasibility of intraoperative lymphatic map-
ping by administration of isosulfan blue dye in 2 case series of 9
and subsequently 21 patients.4,5 However, larger studies from
other tumor entities such as cutaneous melanoma and breast
cancer showed that the combination of intraoperatively ad-
ministered blue dye and preoperatively injected radioactive
tracer (Tc99m) with intraoperative gamma probe detection is
superior to blue dye alone.6Y8With the combined technique, the
SLN identification rate is generally very high with a sensitivity
of 95% (95% confidence interval [CI], 92%Y98%) and a
negative predictive value of 97.9.9,10 Ideally, with the SLN
technique, only 1 node should be identified for excision to keep
morbidity low. Invulvar cancer however, oftenmultiple, up to 7
SLN nodes per groin are identified11 and are consequently
excised to guide further groin treatment.12,13 Thereby,morbidity
potentially is increased with recurrent seroma, lymphedema,
wound breakdown, or erysipelas despite of node-negative dis-
ease. Theoretically, the SLN with the highest isotope count
(‘‘hottest’’ SLN) should be most likely to harbor tumor cells.
However, in breast cancer, the false-negative rate for detection
of SLN metastases was shown to be very variable if only the
hottest SLN is removed (range, 9%Y29%).14Y20 Currently, the
10% rule is the most widely accepted in breast cancer, meaning
that all nodes with more than 10% of the ex vivo isotope count
of hottest SLN should be removed, lowering the false-negative
rate to 2.5% to 6.4%.14,19,20 The 10% rule was also applied in
1184 early stage cutaneous melanoma patients subjected to
SNB.21 The false-negative rate significantly decreased from
13.9% to 0.4% by using the 10% rule compared with removing
the hottest SLN only.
In vulvar cancer, the correlation of the isotope count
with the presence of metastases remains unclear. The aim of
this analysis was therefore to assess whether resection of the
hottest node would be sufficient to reliably detect SLN me-
tastases in vulvar cancer.
MATERIALS AND METHODS
Patient Population
Consecutive patients with squamous cell vulvar cancer
undergoing successful SNB with radioactive tracer from 2008
to 2015 at the Gynecological Cancer Center in Hamburg,
Germany were included in the analysis. Informed consent had
been obtained from all included patients to review their
medical records according to our investigational review board
and ethics committee guidelines (Ethics Committee of the
Medical Board Hamburg reference number 190504). The
institutional approach to the surgical treatment of vulvar
cancer during the investigational period consisted of radical
excision of the primary tumor; the SLN procedure was offered
to patients with locally restricted disease and clinically neg-
ative groin nodes according to the inclusion criteria of the
GROINSS study published in 2008.1 Three patients originally
planned for SNB were subsequently excluded from the
analysis. In the first patient, bilateral SNB was not successful
owing to prior surgery in 1 groin. Instead she received an
inguinofemoral lymphadenectomy (LAE) in that groin. In the
other 2 patients, no SLN could be identified in planar
lymphoscintigraphy preoperatively. Intraoperatively, lymph
nodes were suspicious and metastatic in frozen section so that
bilateral inguinofemoral LAE was performed. All pathological
studies were performed by specialized gynecopathologists.
Clinical outcome was followed from the date of primary
surgery to the date of death or until June 2016. For tumor
staging, the International Federation of Gynecology and
Obstetrics stage groupings as well as the International
Union Against Cancer tumor-node-metastasis classifica-
tion sixth edition were used for homogeneity.22,23
Sentinel Node Detection
The day before surgery, all patients received a con-
ventional planar lymphoscintigraphy of the groins. For that
purpose, 4 peritumoral intradermal deposits (0.2Y0.3 mL
volume each) at 3, 6, 9, and 12 o’clock were placed, using a
27-gauge needle. An overall mean T SDdosage of 85 T 12MBq
99mTc-nanocolloid was injected. One hour after injection,
anterior and lateral static views were obtained for planar
lymphoscintigraphy. The sites of the SLNswere marked on the
skin. Images were made using a large field-of-view dual-head
gamma scintillation camera (ECAM, SiemensMedical Solutions,
Hoffman Estates, Ill) equipped with a low-energy high-resolution
parallel-hole collimator with the following imaging parameters:
matrix sizeof256 256andenergywindowat141keVwith15%
width, 5 minutes each.
On the following day, a handheld gamma counter
(NavigatorGPS, RMD Instruments) was used intraoperatively to
identify the SLNs. After removal of the first SLN, the groin was
reexamined for residual radioactivity, and potentially further
SLNs were removed. Radioactivity was measured, and the re-
spective activity was documented for every single node in the
study. Identified SLNs were sent for frozen section to the
gynecopathologists; if they came back negative, no further node
dissectionwas performed in themajorityof patients.Ultrastaging
of all negative SLNs obtained was performed postoperatively
according to the GROINSS-VI study to identify further me-
tastases as described previously.1 In case of positive SLN in
ultrastaging, a systematic unilateral or bilateral LAE was
performed during a second surgical intervention.
Statistical Analysis
Difference in median isotype count was calculated by
Wilcoxon rank sum test. Survival probabilities were calcu-
lated by Kaplan-Meier curves and log-rank test. An > level of
0.05 was used to assess statistical significance.
RESULTS
Patient Characteristics
A total of 145 patients with successful SNB (144 bi-
lateral and 1 unilateral SNB) during the investigational period
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TABLE 1. Patient characteristics
Characteristics Total (n = 145) Total (%) N0 (n = 100) N0 % N+ (n = 45) N+ (%)
Age at FD, median, y 57 n.a. 57 n.a. 56 n.a.
(range) (20Y88) (20Y85) (26Y88)
Tumor stage
pT1b 116 80 84 84 33 73.3
pT1a 5 2.7 4 4 0 0
pT2 20 13.7 11 11 9 19.6
pT3 4 2.7 1 1 3 6.5
Unilateral groin metastases 39 26.9 n.a. n.a. 39 86.7
Bilateral groin metastases 6 4.14 n.a. n.a. 6 13.3
Unilateral SLN metastases 38 26.2 n.a. n.a. 38 84.4
Bilateral SLN metastases 6 4.14 n.a. n.a. 6 13.3
Median tumor diameter, mm 18 n.a. 14 n.a. 21 n.a.
(range) (1.2Y75) n.a. (1.2Y65) n.a. (2Y75) n.a.
Unknown 10 n.a. 9 n.a. 1 n.a.
Median depth of invasion, mm 3 n.a. 2.6 n.a. 4 n.a.
(range) (0.4Y27) n.a. (0.4Y18) n.a. (1.1Y27) n.a.
Unknown 9 n.a 6 n.a. 3 n.a
Median size of lymph node metastasis, mm 2.5 n.a. n.a. n.a. 2.5 n.a.
(range) 0.15Y26 n.a. n.a. n.a. 0.15Y26 n.a.
Unknown 6 n.a n.a n.a 6 n.a
Resection status of vulvar primary
R0 140 96.6 97 97 43 95.6
R1 0 0 0 0 0 0
VIN in margin 4 2.7 2 2 2 4.35
Unknown 1 0.68 1 1 0 0
Grading
G1 6 4.1 6 6 0 0
G2 99 68.3 71 71 28 62.2
G3 38 26 21 21 17 37
Unknown 2 1.4 2 2 0 0
Vulvar surgery
Vulvectomy 11 7.5 5 5 6 13
Radical local excision 133 91.7 94 94 39 86.7
No local surgery 1 0.68 1 1 0 0
Pelvic node dissection 1 0.68 0 0 1 2.2
Adjuvant therapy
Radiotherapy 15 11 0 0 15 34.8
Chemoradiation 4 2.8 0 0 4 8.9
Laser 2 1.37 2 2 0 0
Radiation field
Vulva/Tgroin/Tpelvis 17 11.7 1 1 17 37.8
Groin only 3 2.1 0 0 3 6.7
No adjuvant therapy 124 85 99 99 25 54.4
(continued on next page)
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(2008Y2015) were included in this analysis, resulting in 289
analyzed groins. Median follow-up (FU) was 30 months
(range, 0.1Y101 months). Detailed patient characteristics are
listed in Table 1. Four patients received bilateral SNB despite
a pT1a vulvar cancer due to lymphangioinvasion diagnosed in
the primary tumor; the excised SLNs of these were all neg-
ative. Ten patients presented with a primary tumor size greater
than 40 mm (range, 41Y75 mm; median, 55 mm) in definitive
histology; 4 of these had a positive SLN and received a
consecutive inguinofemoral LAE (3 bilateral, 1 unilateral).
After a median FU of 21 months, none of those 10 patients
had developed a groin recurrence. However, 1 patient suffered
from distant metastases to the lungs and died 19 months later.
Groin Characteristics
The majority of patients in this analysis received an
SNB only (n = 101, 69.2%). Of these, 100 were node negative
and did not require further treatment (Table 2). Median
number of excised SLNs per groin was 2 (287 groins; range,
1Y7; in 2 groins, the number of excised SLN was unknown)
(Table 2). However, in 94 (32.5%) of 289 groins, more than 2
SLNs were excised. In 50 (17.3%) of 289 groins, a positive
SLN was detected (unilateral in 38 patients, bilateral in 6).
The median number of positive SLN per groin was 1 (range,
1Y4). A total of 45 patients presented with lymph node me-
tastases (39 patients unilateral, 6 bilateral); thereof, 1 had a
non-SLN metastasis only. Of 44 SLN-positive patients, 36
patients had a second bilateral and 7 patients had a unilateral
inguinofemoral LAE owing to small strictly unilateral tumors
or ipsilateral micrometastasis with contralateral negative
SLN. None of these 7 patients presented with a groin recur-
rence after a median of 21 months. One patient presented with
a 1.5-mm SLN metastasis but did not receive a consecutive
inguinofemoral LAE owing to comorbidities. This patient
presented in a poor general condition and died owing to a
stroke 11 months after diagnosis. In patients undergoing a
complete groin dissection, a median of 10 lymph nodes per
groin were dissected (range, 1Y23; 83 groins). The median
number of positive lymph nodes per groin was 1 in node
positive patients (range, 1Y5; 51 groins).
Three patients suffered from isolated groin recurrence
after 5, 17, and 25months. Thereof, 1 patient initially presented
with microinvasive disease (pT1a) and negative bilateral SLN.
She suffered from groin recurrence 25 months after initial di-
agnosis and received only unilateral complete groin dissection
and radiation owing to comorbidities. She died from vulvar
cancer 5 months after groin recurrence. The second patient was
66 at first diagnosis and presented with a pT1b squamous cell
tumor (14mm,G3). She received a bilateral SNB (0/4SLN) and
wide excision of the tumor.Unilateral groin recurrence occurred
after 5 months. The third patient was 48 at initial diagnosis and
also presentedwith a pT1b, 10mmsquamous cell vulvar cancer.
She received a wide excision and SNB (0/3SLN). Groin re-
currence occurred 17months after first diagnosis. Both patients
received bilateral radical groin dissection and consecutive
chemoradiation with cisplatin (40 mg/m2) to the groins and
pelvis.Theywere still alivewith noevidenceofdisease at 22and
49 months after groin recurrence, respectively. Both patients
received bilateral complete groin dissection and consecutive
chemoradiation to the groinswith cisplatin. Theywere still alive
at last FU 22 and 49months after groin recurrence, respectively.
Two- and 3-year disease-free survival was 86.1% (95%
CI, 0.79Y0.94) and 80.7% (95% CI, 0.72Y0.9) in node-
negative patients with SNB only (n = 100) and 77.5%
(95%CI, 0.65Y0.92) and 74.4% (95%CI, 0.61Y0.89) in node-
positive patients (n = 45), respectively (P = 0.33 for 3-year
disease-free survival; Fig. 1). Five-year OS was 90.9%
(95% CI, 0.84Y0.98) in node-negative and 82.6% (95% CI,
0.69Y0.99) in node-positive patients.
Sentinel Isotope Count
Median overall SLN isotope count was 1400 cps. There
was no difference of median count in negative compared with
positive SLN (median count 1396 cps vs 1614 cps; P = 0.90).
The SLN with the highest isotope count carried metastases in
36 (78.0%) of 46 groins (in 4 cases the highest count was
unknown). In 10 (25.0%) of 46 positive groins, the SLN with
the highest count was not the metastatic SLN (in 9/10 second
highest count). Median count of these 10 SLNwas 60% of the
highest count with a range from 11.0% to 74.0% (Supple-
mentary Table 1, http://links.lww.com/IGC/A752).
DISCUSSION
Despite numerous studies that confirmed the accuracy
of SNB for assessment of the nodal status, the optimum
technique of SNB in vulvar cancer still remains a matter of
debate. In vulvar cancer, high background activity often leads
to removal of greater than 2 SLNs and therefore might in-
crease morbidity despite node-negative disease. The present
analysis shows that the highest isotope count correlates with
SLN metastases in the majority of cases (75%); however, it
does not reliably predict SLN metastases in all patients. With
the application of the 10% rule suggested by other authors
primarily for breast cancer or malignant melanoma,14,19Y21 no
SLNmetastases would have been missed in our cohort (lowest
TABLE 1. (Continued)
Characteristics Total (n = 145) Total (%) N0 (n = 100) N0 % N+ (n = 45) N+ (%)
Neoadjuvant RTX 1 0.68 1 1 0 0
Median FU, mo 30 n.a. 31.5 n.a. 28.5 n.a.
(range) (0.1Y101) n.a. (0.1Y101) n.a. (1Y73) n.a.
n.a., not applicable; FD, first diagnosis; RTX, chemoradiation.
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isotope count of the SLN that contained metastases: 11% of the
highest count). In our cohort, only 1 patient presented with an
SLNmetastases in the third hottest SLNnode,which still showed
25% of the isotope count of the hottest SLN (269/1073 cps).
There is no clear consensus in national guidelines regarding
the number of SLN nodes that should be excised, and intra-
operatively surgeons are often faced with the decision to re-
move a fourth or fifth mildly active node. However, the 10%
rulewas already part of the sentinel node detection protocol in
theGROINSS-VI studies. After removal of the sentinel nodes,
the biopsy bed was reexamined for radioactivity, and if higher
than 10% of the first excised lymph node, the dissection was
continued in search of additional sentinel nodes. Protocols for
the absolute dose of 99Tc nanocolloid injection have largely
been adapted from breast cancer and melanoma. They differ
between countries and institutions (50Y100 MBq total dose
per injection spot). In vulvar cancer, the SLN procedure has
initially been performed combining radioactive tracer and
blue dye and therewith yielded highly accurate detection rates
(98%Y100%).24 New guidelines do not mandatory require
blue dye.25,26 Compared with breast cancer and melanoma,
the SLN detection rate in vulvar cancer is even more accurate.
In a meta-analysis of 8059 patients with breast cancer, 96%
had successfully mapped SLNs. However, in more than 50%
of included breast cancer studies, detection rates of greater
than 90% were reported.27 A possible explanation for the
higher identification rate in vulvar cancer24 might be the
anatomy of the lymphatic channels to the inguinofemoral
TABLE 2. Groin characteristics
Groin Characteristics N = 145 Patients %
Groin surgery
Full groin dissection (unilateral or bilateral)
SLN+ followed by unilateral groin dissection 7 4.8
SLN+ followed by bilateral groin dissection 36 24.8
SLN+ no groin dissection due to comorbidity 1 0.69
Non-SLN positive followed by bilateral groin dissection 1 0.69
SLN
Patients with unilateral excised SLN 1 0.69
Patients with bilateral excised SLN 144 99.3
Patients with unilateral positive SLN 38 26.2
Patients with bilateral positive SLN 6 4.1
SLN counts per groin (46 groins plus 4 unknown count)
Groins with positive SLN highest count 36 78.3
Groins with other positive SLN 10 21.7
Groins with SLN count unknown 4 (4/50 groins) 8
SLN counts
Counts SLN+ (median) range 1614 (74Y10,721) n.a.
Counts SLNj (median) range 1396 (4Y17,412) n.a.
Excised lymph nodes per groin (only pat. with full groin dissection)
Median (range) 10 (1Y23) n.a.
No. groins 81 n.a.
Positive lymph nodes per groin (only pat. with full groin dissection)
Median (range) 1 (1Y5) n.a.
No. groins 51 n.a.
Excised sentinel nodes/groin
Median (range) 2 (1Y7) n.a.
No. groins 287 n.a.
No. excised sentinel nodes unknown 2 n.a.
Positive sentinel nodes/groin
Median (range) 1 (1Y4) n.a.
No. groins 50 n.a.
Isolated groin recurrence 3 2.1
SLN+, positive sentinel lymph node; SLNj, negative sentinel lymph node; n.a., not applicable.
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nodes, which seem to vary only minimally, and the SLN is
almost always located above the cribriform fascia of the fossa
ovalis. The nodal recurrence risk, however, seems less fa-
vorable in vulvar cancer when compared with breast cancer
(2.3%vs 0.1%Y0.3%).28 Thismight be partly explained by the
fact that the majority of breast cancer patients will receive
adjuvant treatment, whereas node-negative vulvar cancer
patients will not. Therefore, the accuracy of SLN detection
technique is even more important, as lethality of nodal re-
currence in vulvar cancer is high. Some authors proposed the
use of bigger particles like colloidal albumin or (99m)Tc-
phytate in comparison with Technetium. Sentinel lymph node
number is closely related to the size of the radiocolloid used,29
and bigger particles might not get so easily into other nodes
than into the sentinel node. New surgical techniques to
identify the SLNmay be of additional value for intraoperative
imaging of the SLN in vulvar cancer. Recently, intraoperative
near-infrared fluorescence (NIRF) imaging was introduced as
a new technique for SLN detection. This approach is based on
the intraoperative injection of a fluorescent agent around the
primary tumor, which will flow through the lymphatic vessels
and accumulate in the SLN(s). Upon excitation with a laser
beam, the agent emits light of a longer wavelength, which is
captured and processed by a fluorescence camera. Real-time
images can be displayed on monitors in the operating theatre.
Currently, the fluorescent agent of choice is indocyanin green,
a Food and Drug AdministrationYapproved agent with little
toxicity that has been used for decades for ophthalmic angi-
ography and evaluation of liver perfusion. In different pilot
studies, this technique has been investigated for gynecological
malignancies, for example, vulvar cancer.30Y34 In 70 patients
with vulvar cancer that have been described in 5 clinical studies,
96.6% of SLN detected by 99mTc nanocolloid were also fluo-
rescent in vivo. This was in contrast to blue dye, which stained
only 70.6%of theSLNs (PG 0.001).However, in a pilot studyby
Crane et al,30 detection rates in obese patients were limited,
owing to the limited penetration depth of NIRF. In total, 29
SLNs were detected by radiocolloid, of which 26 were also
detected by fluorescence and 21 were blue. The authors con-
clude that these first clinical results indicate that intra-
operative transcutaneous lymphaticmapping using fluorescence
is technically feasible in a subgroup of lean vulvar cancer
patients. Currently, indocyanin green is the only Food and
Drug AdministrationYapproved NIRF agent. Future research
on intraoperative fluorescence imaging for SLN detection may
benefit from fluorescent agents with stronger penetration prop-
erties. Results of larger clinical studies especially concerning
the oncologic safety (false-negative rate) and number of re-
moved SLNs are still pending.
This retrospective analysis shows that the hottest SLN
has the highest likelihood of harboring the tumor cells in
vulvar cancer. In all other cases except for one, the second
hottest SLN contained the tumor cells. However, because
groin recurrences in vulvar cancer are almost always fatal,
oncologic safety has to be balanced carefully against the
potentially increased morbidity of a fourth or fifth excised
sentinel. Based on the results of this study, it is not sufficient
to remove the hottest sentinel node only and surgeons should
follow the 10% rule known from other entities as a guidance.
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